Moderna’s chief commercial officer Arpa Garay has left her role as the company moves to “increase executive focus” on sales, it announced Tuesday morning.
The company reaffirmed its focus on driving Covid-19 and soon RSV vaccine sales, though the former’s sales have been challenged by waning demand. Moderna said last month that it expects Covid sales to “hit a low point” in 2024, while Pfizer recently slashed expectations for its Comirnaty shot by $2 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.